HOME >> MEDICINE >> NEWS
UIC developing drug for SARS

A prototype drug created by researchers at the University of Illinois at Chicago shows promise in slowing replication of the virus responsible for severe acute respiratory syndrome, or SARS.

Currently, there are no effective antiviral agents or vaccines for SARS, which killed almost 800 people in an epidemic in 2002-2003.

On the basis of their success, the researchers have received an $8 million grant from the National Institute of Allergy and Infectious Diseases to develop protease inhibitors that would block key enzymes in the SARS virus and hamper its advance. Protease inhibitors, a class of drugs capable of disrupting enzymes that digest proteins, have been successfully used to thwart the human immunodeficiency virus, which causes AIDS.

"Data from SARS patients indicate that replication of the virus peaks 10 days after the onset of fever," said Michael Johnson, director of the Center for Pharmaceutical Biotechnology in the UIC College of Pharmacy and the study's principal investigator. "By administering protease inhibitors early, when feverish symptoms have started, the drugs could reduce the viral load and ameliorate the disease."

Like HIV, the SARS virus multiplies rapidly, hijacking the machinery of the cells it infects to clone itself over and over again.

One of the first steps in that process is the production of a long chain of proteins, all of which are needed for the virus to propagate. Two enzymes, or proteases, clip the chain to release the individual proteins, the parts needed to assemble a mature virus.

These two proteases -- called 3CLpro and PLpro -- are UIC's targets for drug therapy.

"If we can block 3CLpro and probably PLpro, then we can stop the SARS virus from replicating," Johnson said.

Under the grant, Andrew Mesecar, associate professor of pharmacy, will study details of the three-dimensional structure of the two enzymes using x-ray crystallography.

His technique invol
'"/>

Contact: Sharon Butler
sbutler@uic.edu
312-355-2522
University of Illinois at Chicago
8-Jun-2005


Page: 1 2 3

Related medicine news :

1. Program announced to improve care in developing areas for patients with blood disorders
2. Caring for the sick now a public health priority for developing countries
3. Over time, more women are developing MS than men
4. Addressing the neglect of childhood hearing impairment in developing countries
5. First step in developing heart hormone-based pill to control high blood pressure
6. USC-led study suggests exercise reduces risk of developing invasive breast cancer
7. Cells passed from mother to child may be first step in developing new treatments for type 1 diabetes
8. Tuberculosis risks for health workers in developing countries
9. Global strategies to improve health in developing countries need truly global discussions
10. Adolescent smokers have a greater risk of developing alcohol-use disorders than nonsmokers
11. Measuring brain activity for emotional markers that may indicate risk for developing alcoholism

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UIC developing drug for SARS

(Date:8/2/2015)... ... 2015 , ... Molecular biologists in New South Wales say a protein linked ... just posted an article on the new research. Click here to read it ... expression in tissue samples from 42 patients with peritoneal mesothelioma and found a direct ...
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... CA (PRWEB) , ... August 01, 2015 , ... Have you ever wondered what “Karma” ... when you hear the word “Karma.” , Vedic tradition, which gave birth to Hinduism, ... is one of the central concepts of this tradition. According to the wisdom of this ...
(Date:8/1/2015)... ... , ... Calvary Hospital today announced that it is embarking on a yearlong ... to bring this Torah – dating from 1880 – back to kosher status, so ... , Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan to ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of ... unification of their Healthy Home mission with the HOPE Movement of EvolvHealth. In what ... of both companies have agreed to join their missions of purpose together to change ...
Breaking Medicine News(10 mins):Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 Edwards ... the science of heart valves and hemodynamic monitoring, today announced ... company,s Board of Directors. "Bob is an ardent ... been a true privilege to have him on Edwards, board ... A. Mussallem , Edwards, chairman and CEO.  "Bob has provided ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
Cached News: